Delving into the Latest Updates on Suzhou Ruihe Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Peptide Conjugate Radionuclide

Therapeutic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Peptide Conjugate Radionuclide	2
Therapeutic radiopharmaceuticals	2

Top 5 Target	Count

PSMA(Prostate-specific membrane antigen)	2

[Translation] A single-arm, open-label, dose-escalation, and expansion phase I/II clinical trial evaluating the safety, tolerability, clinicophagus pharmacology, and preliminary efficacy of gallium [68Ga]PSMA-0057 injection and lutetium [177Lu]PSMA-0057 injection in patients with PSMA-positive metastatic castration-resistant prostate cancer.

I期主要目的：在PSMA阳性的转移性去势抵抗性前列腺癌（mCRPC）患者中评价镓[68Ga]PSMA-0057注射液和镥[177Lu]PSMA-0057注射液作为诊疗一体化方案的安全性和耐受性，并确定177Lu-PSMA-0057最大耐受剂量（MTD）和/或II期临床试验推荐给药方案。 II期主要目的：在PSMA阳性的mCRPC患者中评价68Ga-PSMA-0057注射液和177Lu-PSMA-0057注射液作为诊疗一体化方案的初步有效性。

[Translation]

Phase I Primary Objective: To evaluate the safety and tolerability of gallium [68Ga]PSMA-0057 injection and lutetium [177Lu]PSMA-0057 injection as a therapeutic regimen in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), and to determine the maximum tolerated dose (MTD) of 177Lu-PSMA-0057 and/or the recommended dosing regimen from the Phase II clinical trial. Phase II Primary Objective: To evaluate the preliminary efficacy of 68Ga-PSMA-0057 injection and 177Lu-PSMA-0057 injection as a therapeutic regimen in patients with PSMA-positive mCRPC.

Start Date-

Sponsor / Collaborator

Suzhou Ruihe Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Suzhou Ruihe Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Ruihe Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Ruihe Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Ruihe Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

2

Login to view more data